This week a groundbreaking partnership was announced between UNC-Chapel Hill, a leader at the forefront of AIDS research, and GlaxoSmithKline, one of the top producers of HIV drugs, to create a new venture that will leverage government funds, private investment and research to accelerate the search to eradicate AIDS.
The partnership will establish The HIV Cure Center housed on Chapel Hill’s campus and initially employ about 50 scientists. The center will use a new method called “shock and kill,” which makes “the hidden HIV virus visible to the immune system and allows the patient’s immune system to clear the virus.”
For many years, UNC has served as hub for the nation’s AIDs research as the host institution of a national collaborative project funded by the National Institutes of Health. In the years to come, scientists at other colleges and universities will work on projects and research with UNC’s scientists.